Francis Pang is Vice President and Head, Global Market Access at Orchard Therapeutics and has more than 20 years of experience in pricing and reimbursement, market access and health economics, encompassing leadership roles at Amicus Therapeutics, Biogen and Shire HGT. In recognition of his expertise related to rare diseases, Francis has served as the healthcare industry representative on the NICE Highly Specialised Technologies (HST) Committee since its inception. He also co-chairs the European Market Access and Value Committee of the Alliance for Regenerative Medicine (ARM). Prior to joining the biopharmaceutical industry, Francis was the inaugural Pharmacoeconomics Research Fellow at the Centre for Health Economics, University of York, UK and Monbusho Scholar at Kyoto University, Japan. Francis holds degrees in genetics and health economics, together with an MBA from INSEAD and certification in the management of biotech ventures from École Polytechnique Fédérale de Lausanne (EPFL).